{"protocolSection": {"identificationModule": {"nctId": "NCT00666679", "orgStudyIdInfo": {"id": "0476-386"}, "secondaryIdInfos": [{"id": "MK0476-386"}, {"id": "2007_654"}], "organization": {"fullName": "Organon and Co", "class": "INDUSTRY"}, "briefTitle": "Study of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma (0476-386)", "officialTitle": "Randomized, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Inhaled Corticosteroid Plus Montelukast Compared With Inhaled Corticosteroid Therapy Alone in Patients With Chronic Asthma"}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-05"}, "primaryCompletionDateStruct": {"date": "2009-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-04-23", "studyFirstSubmitQcDate": "2008-04-23", "studyFirstPostDateStruct": {"date": "2008-04-25", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-01-07", "resultsFirstSubmitQcDate": "2010-01-07", "resultsFirstPostDateStruct": {"date": "2010-02-03", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2024-05-07", "lastUpdatePostDateStruct": {"date": "2024-05-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Organon and Co", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "This study assesses inhaled corticosteroid plus montelukast compared with inhaled corticosteroid therapy alone for treatment of patients with chronic asthma.", "detailedDescription": "During this study, all patients will receive mometasone (powder, 220 mcg once-daily, for approximately 6 weeks). In a crossover manner, eligible patients will also receive montelukast (powder, 1 mg once-daily, for approximately 2 weeks) followed by placebo; or will receive placebo followed by montelukast. The order of when each of these 2 treatments are added to the mometasone will be randomized."}, "conditionsModule": {"conditions": ["Asthma"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 134, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "1", "type": "ACTIVE_COMPARATOR", "description": "mometasone", "interventionNames": ["Drug: Comparator: mometasone"]}, {"label": "2", "type": "PLACEBO_COMPARATOR", "description": "montelukast followed by placebo; or placebo followed by montelukast.", "interventionNames": ["Drug: Comparator: montelukast", "Drug: Comparator: placebo (unspecified)"]}], "interventions": [{"type": "DRUG", "name": "Comparator: mometasone", "description": "mometasone (inhalation powder, 220 mcg once-daily, for approximately 6 weeks)", "armGroupLabels": ["1"]}, {"type": "DRUG", "name": "Comparator: montelukast", "description": "montelukast (inhalation powder, 1 mg once-daily, for approximately 2 weeks)", "armGroupLabels": ["2"]}, {"type": "DRUG", "name": "Comparator: placebo (unspecified)", "description": "Placebo (Placebo once-daily, for approximately 2 weeks)", "armGroupLabels": ["2"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in FEV1 (Forced Expiratory Volume; Volume of Air That is Exhaled During the First Second of a Forced Exhalation)", "description": "To determine the effect of 2 weeks of treatment with inhaled montelukast plus mometasone and mometasone alone on bronchodilation assessed by average change from baseline in FEV1 over the 2 week treatment period; measurements taken at 1 and 2 weeks contributed to the average.", "timeFrame": "Baseline and 2 weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Daytime Asthma Symptom Score", "description": "To determine the effect of 2 weeks of treatment with inhaled montelukast plus mometasone and mometasone alone on asthma symptoms assessed by average change from baseline in daytime asthma symptom score (which could range from 0 \\[best\\] to 6 \\[worst\\]) over the 2 week treatment period; measurements taken at 1 and 2 weeks contributed to the average.", "timeFrame": "Baseline and 2 weeks"}, {"measure": "Change From Baseline in Nighttime Asthma Symptom Score", "description": "To determine the effect of 2 weeks of treatment with inhaled montelukast plus mometasone and mometasone alone on asthma symptoms assessed by average change from baseline in nighttime asthma symptom score (which could range from 0 \\[best\\] to 3 \\[worst\\]) over the 2 week treatment period; measurements taken at 1 and 2 weeks contributed to the average.", "timeFrame": "Baseline and 2 weeks"}], "otherOutcomes": [{"measure": "Change From Baseline in Total Daily \u03b2-agonist Use", "description": "To determine the effect of 2 weeks of treatment with inhaled montelukast plus mometasone and mometasone alone on as-needed \u03b2-agonist use assessed by average change from baseline in total daily \u03b2-agonist use over the 2 week treatment period; measurements taken at 1 and 2 weeks contributed to the average.", "timeFrame": "Baseline and 2 weeks"}, {"measure": "Percentage of Days With Asthma Control", "description": "To determine the effect of 2 weeks of treatment with inhaled montelukast plus mometasone and mometasone alone on asthma control assessed by average percentage of days with asthma control over the 2 week treatment period; measurements taken at 1 and 2 weeks contributed to the average.", "timeFrame": "2 weeks"}, {"measure": "Percentage of Days With Asthma Exacerbations", "description": "To determine the effect of 2 weeks of treatment with inhaled montelukast plus mometasone and mometasone alone on worsening of asthma assessed by percentage of days with asthma exacerbations during the 2 week treatment period.", "timeFrame": "2 Weeks"}, {"measure": "Change From Baseline in Total Peripheral Blood Eosinophils", "description": "To determine the effect of 2 weeks of treatment with inhaled montelukast plus mometasone and mometasone alone on change from baseline in total peripheral blood eosinophils during the 2 week treatment period.", "timeFrame": "Baseline and 2 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient has decreased breathing capacity (when not taking asthma medicine) that improves after taking a fast-acting asthma inhaler\n* Within one month of the first study visit, patient has been treated with a fast-acting asthma inhaler, and may be treated with a corticosteroid inhaler or an inhaler that combines a corticosteroid plus a bronchodilator\n\nExclusion Criteria:\n\n* Patient is hypersensitive to inhaled beta-agonists, corticosteroids, leukotriene antagonists, or any of their components\n* Has required an oral corticosteroid rescue for worsening asthma during the screening period", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "15 Years", "maximumAge": "85 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "21545249", "type": "RESULT", "citation": "Philip G, Villaran C, Shah SR, Vandormael K, Smugar SS, Reiss TF. The efficacy and tolerability of inhaled montelukast plus inhaled mometasone compared with mometasone alone in patients with chronic asthma. J Asthma. 2011 Jun;48(5):495-502. doi: 10.3109/02770903.2011.573042. Epub 2011 May 5."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "278 participants were screened; 144 were excluded.\n\nRandomized patients met the following criteria: FEV1 (Forced expiratory volume in one second) 50-80% predicted while withholding short-acting beta agonist (SABA) and reversibility of airway obstruction \\>12% following SABA documented on at least two of the following visits: Visits 1, 2, and 3.", "recruitmentDetails": "Patients were recruited from 25 centers worldwide. Patient screening began 05-May-2008 and the first patient was randomized on 29-May-2008.\n\nThe last patient's last visit was completed on 16-Feb-2009.", "groups": [{"id": "FG000", "title": "Montelukast + Mometasone Then Placebo + Mometasone", "description": "Patients were randomized to receive montelukast 1 mg (milligram) and open-label mometasone 220 mcg (micrograms) once daily by inhalation in the first intervention; and placebo for montelukast and open-label mometasone 220 mcg once daily by inhalation in the second intervention (after washout). During washout, patients received open-label inhaled mometasone 220 mcg and single-blind placebo for montelukast once daily by inhalation."}, {"id": "FG001", "title": "Placebo + Mometasone Then Montelukast + Mometasone", "description": "Patients were randomized to receive placebo for montelukast and open-label mometasone 220 mcg once daily by inhalation in the first intervention; and montelukast 1 mg and open-label mometasone 220 mcg once daily by inhalation in the second intervention (after washout). During washout, patients received open-label inhaled mometasone 220 mcg and single-blind placebo for montelukast once daily by inhalation."}], "periods": [{"title": "First Intervention", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "66"}, {"groupId": "FG001", "numSubjects": "68"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "62"}, {"groupId": "FG001", "numSubjects": "67"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Randomized did not start treatment", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}]}, {"title": "Washout Period of 1 Week", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "62"}, {"groupId": "FG001", "numSubjects": "67"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "62"}, {"groupId": "FG001", "numSubjects": "65"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}, {"title": "Second Intervention", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "62"}, {"groupId": "FG001", "numSubjects": "65"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "61"}, {"groupId": "FG001", "numSubjects": "64"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Montelukast + Mometasone Then Placebo + Mometasone", "description": "Patients were randomized to receive montelukast 1 mg (milligram) and open-label mometasone 220 mcg (micrograms) once daily by inhalation in the first intervention; and placebo for montelukast and open-label mometasone 220 mcg once daily by inhalation in the second intervention (after washout). During washout, patients received open-label inhaled mometasone 220 mcg and single-blind placebo for montelukast once daily by inhalation."}, {"id": "BG001", "title": "Placebo + Mometasone Then Montelukast + Mometasone", "description": "Patients were randomized to receive placebo for montelukast and open-label mometasone 220 mcg once daily by inhalation in the first intervention; and montelukast 1 mg and open-label mometasone 220 mcg once daily by inhalation in the second intervention (after washout). During washout, patients received open-label inhaled mometasone 220 mcg and single-blind placebo for montelukast once daily by inhalation."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "66"}, {"groupId": "BG001", "value": "68"}, {"groupId": "BG002", "value": "134"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "39.2", "spread": "15.5"}, {"groupId": "BG001", "value": "42.6", "spread": "14.8"}, {"groupId": "BG002", "value": "40.9", "spread": "15.2"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "37"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "69"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "36"}, {"groupId": "BG002", "value": "65"}]}]}]}, {"title": "Daytime Asthma Symptom Score (0 [best] to 6 [worst] Point Scale)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Units on a Scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.04", "spread": "0.90"}, {"groupId": "BG001", "value": "2.18", "spread": "0.81"}, {"groupId": "BG002", "value": "2.11", "spread": "0.85"}]}]}]}, {"title": "FEV1 (Forced Expiratory Volume in One Second)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "L (Liter)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "2.14", "spread": "0.67"}, {"groupId": "BG001", "value": "2.18", "spread": "0.55"}, {"groupId": "BG002", "value": "2.16", "spread": "0.61"}]}]}]}, {"title": "Nighttime Asthma Symptom Score (0 [best] to 3 [worst] Point Scale)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Units on a Scale", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.51", "spread": "0.53"}, {"groupId": "BG001", "value": "0.46", "spread": "0.48"}, {"groupId": "BG002", "value": "0.49", "spread": "0.50"}]}]}]}, {"title": "Total Daily Beta-Agonist Use", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Puffs", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "3.52", "spread": "2.49"}, {"groupId": "BG001", "value": "3.55", "spread": "2.19"}, {"groupId": "BG002", "value": "3.53", "spread": "2.34"}]}]}]}, {"title": "Total Peripheral Blood Eosinophils", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "10^3/microliters", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "0.46", "spread": "0.39"}, {"groupId": "BG001", "value": "0.38", "spread": "0.31"}, {"groupId": "BG002", "value": "0.42", "spread": "0.35"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in FEV1 (Forced Expiratory Volume; Volume of Air That is Exhaled During the First Second of a Forced Exhalation)", "description": "To determine the effect of 2 weeks of treatment with inhaled montelukast plus mometasone and mometasone alone on bronchodilation assessed by average change from baseline in FEV1 over the 2 week treatment period; measurements taken at 1 and 2 weeks contributed to the average.", "populationDescription": "The analysis was based on the Full analysis set (FAS) population which included all randomized patients who took at least one dose of blinded post randomization study drug (inhaled montelukast or matching placebo) and had a measurement for analysis available in at least one treatment period of the cross-over design.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "L (Liter)", "timeFrame": "Baseline and 2 weeks", "groups": [{"id": "OG000", "title": "Montelukast + Mometasone", "description": "Inhaled montelukast 1mg (milligram) and open label mometasone 220 mcg (micrograms) once daily."}, {"id": "OG001", "title": "Placebo + Mometasone", "description": "Inhaled placebo for montelukast and open label mometasone 220 mcg once daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "127"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.22", "lowerLimit": "0.15", "upperLimit": "0.30"}, {"groupId": "OG001", "value": "0.17", "lowerLimit": "0.11", "upperLimit": "0.23"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.033", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model with fixed effects for treatment, time (weeks 1 and 2), treatment-by-time interaction, period and baseline covariate.", "paramType": "Difference in Least-Squares Means", "paramValue": "0.05", "ciPctValue": "95", "ciLowerLimit": "0.00", "ciUpperLimit": "0.09", "estimateComment": "Least-Squares Means for average change from baseline are derived using appropriate contrast from mixed model with fixed effects for treatment, time (weeks 1 and 2), treatment-by-time interaction, period and baseline covariate."}]}, {"type": "SECONDARY", "title": "Change From Baseline in Daytime Asthma Symptom Score", "description": "To determine the effect of 2 weeks of treatment with inhaled montelukast plus mometasone and mometasone alone on asthma symptoms assessed by average change from baseline in daytime asthma symptom score (which could range from 0 \\[best\\] to 6 \\[worst\\]) over the 2 week treatment period; measurements taken at 1 and 2 weeks contributed to the average.", "populationDescription": "The analysis was based on the FAS population which included all randomized patients who took at least one dose of blinded post randomization study drug (inhaled montelukast or matching placebo) and had a measurement for analysis available in at least one treatment period of the cross-over design.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Units on a Scale", "timeFrame": "Baseline and 2 weeks", "groups": [{"id": "OG000", "title": "Montelukast + Mometasone", "description": "Inhaled montelukast 1mg (milligram) and open label mometasone 220 mcg (micrograms) once daily."}, {"id": "OG001", "title": "Placebo + Mometasone", "description": "Inhaled placebo for montelukast and open label mometasone 220 mcg once daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "129"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.39", "lowerLimit": "-0.49", "upperLimit": "-0.29"}, {"groupId": "OG001", "value": "-0.24", "lowerLimit": "-0.35", "upperLimit": "-0.12"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.005", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model with fixed effects for treatment, time (weeks 1 and 2), treatment-by-time interaction, period and baseline covariate.", "paramType": "Difference in Least-Squares Means", "paramValue": "-0.15", "ciPctValue": "95", "ciLowerLimit": "-0.26", "ciUpperLimit": "-0.05", "estimateComment": "Least-Squares Means for average change from baseline are derived using appropriate contrast from mixed model with fixed effects for treatment, time (weeks 1 and 2), treatment-by-time interaction, period and baseline covariate."}]}, {"type": "SECONDARY", "title": "Change From Baseline in Nighttime Asthma Symptom Score", "description": "To determine the effect of 2 weeks of treatment with inhaled montelukast plus mometasone and mometasone alone on asthma symptoms assessed by average change from baseline in nighttime asthma symptom score (which could range from 0 \\[best\\] to 3 \\[worst\\]) over the 2 week treatment period; measurements taken at 1 and 2 weeks contributed to the average.", "populationDescription": "The analysis was based on a subset of the FAS population which included all randomized patients with nighttime symptoms at baseline (score\\>0), who took at least one dose of blinded post randomization study drug (inhaled montelukast or matching placebo) and had a measurement for analysis available in at least one treatment period.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Units on a Scale", "timeFrame": "Baseline and 2 weeks", "groups": [{"id": "OG000", "title": "Montelukast + Mometasone", "description": "Inhaled montelukast 1mg (milligram) and open label mometasone 220 mcg (micrograms) once daily."}, {"id": "OG001", "title": "Placebo + Mometasone", "description": "Inhaled placebo for montelukast and open label mometasone 220 mcg once daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "89"}, {"groupId": "OG001", "value": "90"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.28", "lowerLimit": "-0.35", "upperLimit": "-0.20"}, {"groupId": "OG001", "value": "-0.18", "lowerLimit": "-0.28", "upperLimit": "-0.09"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.015", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model with fixed effects for treatment, time (weeks 1 and 2), treatment-by-time interaction, period and baseline covariate.", "paramType": "Difference in Least-Squares Means", "paramValue": "-0.09", "ciPctValue": "95", "ciLowerLimit": "-0.17", "ciUpperLimit": "-0.02", "estimateComment": "Least-Squares Means for average change from baseline are derived using appropriate contrast from mixed model with fixed effects for treatment, time (weeks 1 and 2), treatment-by-time interaction, period and baseline covariate."}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline in Total Daily \u03b2-agonist Use", "description": "To determine the effect of 2 weeks of treatment with inhaled montelukast plus mometasone and mometasone alone on as-needed \u03b2-agonist use assessed by average change from baseline in total daily \u03b2-agonist use over the 2 week treatment period; measurements taken at 1 and 2 weeks contributed to the average.", "populationDescription": "The analysis was based on the FAS population which included all randomized patients who took at least one dose of blinded post randomization study drug (inhaled montelukast or matching placebo) and had a measurement for analysis available in at least one treatment period of the cross-over design.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Puffs", "timeFrame": "Baseline and 2 weeks", "groups": [{"id": "OG000", "title": "Montelukast + Mometasone", "description": "Inhaled montelukast 1mg (milligram) and open label mometasone 220 mcg (micrograms) once daily."}, {"id": "OG001", "title": "Placebo + Mometasone", "description": "Inhaled placebo for montelukast and open label mometasone 220 mcg once daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "128"}, {"groupId": "OG001", "value": "128"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.87", "lowerLimit": "-1.21", "upperLimit": "-0.53"}, {"groupId": "OG001", "value": "-0.27", "lowerLimit": "-0.86", "upperLimit": "0.32"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.073", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model with fixed effects for treatment, time (weeks 1 and 2), treatment-by-time interaction, period and baseline covariate.", "paramType": "Difference in Least-Squares Means", "paramValue": "-0.60", "ciPctValue": "95", "ciLowerLimit": "-1.26", "ciUpperLimit": "0.06", "estimateComment": "Least-Squares Means for average change from baseline are derived using appropriate contrast from mixed model with fixed effects for treatment, time (weeks 1 and 2), treatment-by-time interaction, period and baseline covariate."}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Percentage of Days With Asthma Control", "description": "To determine the effect of 2 weeks of treatment with inhaled montelukast plus mometasone and mometasone alone on asthma control assessed by average percentage of days with asthma control over the 2 week treatment period; measurements taken at 1 and 2 weeks contributed to the average.", "populationDescription": "The analysis was based on the FAS population which included all randomized patients who took at least one dose of blinded post randomization study drug (inhaled montelukast or matching placebo) and had a measurement for analysis available in at least one treatment period of the cross-over design.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of Days", "timeFrame": "2 weeks", "groups": [{"id": "OG000", "title": "Montelukast + Mometasone", "description": "Inhaled montelukast 1mg (milligram) and open label mometasone 220 mcg (micrograms) once daily."}, {"id": "OG001", "title": "Placebo + Mometasone", "description": "Inhaled placebo for montelukast and open label mometasone 220 mcg once daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "129"}, {"groupId": "OG001", "value": "129"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "35.13", "lowerLimit": "28.52", "upperLimit": "41.74"}, {"groupId": "OG001", "value": "29.04", "lowerLimit": "22.98", "upperLimit": "35.11"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.004", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model with fixed effects for treatment, time (weeks 1 and 2), treatment-by-time interaction and period.", "paramType": "Difference in Least-Squares Means", "paramValue": "6.08", "ciPctValue": "95", "ciLowerLimit": "1.94", "ciUpperLimit": "10.23", "estimateComment": "Least-Squares Means for average percentage of days are derived using appropriate contrast from mixed model with fixed effects for treatment, time (weeks 1 and 2), treatment-by-time interaction and period."}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Percentage of Days With Asthma Exacerbations", "description": "To determine the effect of 2 weeks of treatment with inhaled montelukast plus mometasone and mometasone alone on worsening of asthma assessed by percentage of days with asthma exacerbations during the 2 week treatment period.", "populationDescription": "The analysis was based on the Completers Set population which included all randomized patients who took a dose of blinded post randomization study drug (inhaled montelukast or matching placebo) in both treatment periods and had a measurement for analysis available in both treatment periods of the cross-over design.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage of Days", "timeFrame": "2 Weeks", "groups": [{"id": "OG000", "title": "Montelukast + Mometasone", "description": "Inhaled montelukast 1mg (milligram) and open label mometasone 220 mcg (micrograms) once daily."}, {"id": "OG001", "title": "Placebo + Mometasone", "description": "Inhaled placebo for montelukast and open label mometasone 220 mcg once daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "127"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.71", "lowerLimit": "5.51", "upperLimit": "13.90"}, {"groupId": "OG001", "value": "15.14", "lowerLimit": "10.94", "upperLimit": "19.33"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "<=0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Model with terms for patient, treatment and period.", "paramType": "Difference in Least-Squares Means", "paramValue": "-5.43", "ciPctValue": "95", "ciLowerLimit": "-8.67", "ciUpperLimit": "-2.19", "estimateComment": "Least-Squares Means for percentage of days are derived from ANCOVA model with terms for patient, treatment and period."}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change From Baseline in Total Peripheral Blood Eosinophils", "description": "To determine the effect of 2 weeks of treatment with inhaled montelukast plus mometasone and mometasone alone on change from baseline in total peripheral blood eosinophils during the 2 week treatment period.", "populationDescription": "The analysis was based on the FAS population which included all randomized patients who took at least one dose of blinded post randomization study drug (inhaled montelukast or matching placebo) and had a measurement for analysis available in at least one treatment period of the cross-over design.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "10^3/microliter", "timeFrame": "Baseline and 2 weeks", "groups": [{"id": "OG000", "title": "Montelukast + Mometasone", "description": "Inhaled montelukast 1mg (milligram) and open label mometasone 220 mcg (micrograms) once daily."}, {"id": "OG001", "title": "Placebo + Mometasone", "description": "Inhaled placebo for montelukast and open label mometasone 220 mcg once daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "119"}, {"groupId": "OG001", "value": "119"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.05", "lowerLimit": "-0.09", "upperLimit": "-0.01"}, {"groupId": "OG001", "value": "0.02", "lowerLimit": "-0.03", "upperLimit": "0.06"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.013", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model with fixed effects for treatment, period and baseline covariate.", "paramType": "Difference in Least-Squares Means", "paramValue": "-0.07", "ciPctValue": "95", "ciLowerLimit": "-0.12", "ciUpperLimit": "-0.01", "estimateComment": "Least-Squares Means for change from baseline are derived from mixed model with terms for treatment, period and baseline covariate."}]}, {"type": "POST_HOC", "title": "Change From Baseline in FEV1 (Forced Expiratory Volume; Volume of Air That is Exhaled During the First Second of a Forced Exhalation) in Patients Who Met Lung Function Eligibility Criteria Specifically at the Randomization Visit.", "description": "To determine the effect of 2 weeks of treatment with inhaled montelukast plus mometasone and mometasone alone on bronchodilation assessed by average change from baseline in FEV1 over the 2 week treatment period in patients who met lung function eligibility criteria at randomization; measurements taken at 1 and 2 weeks contributed to average.", "populationDescription": "The analysis was based on a subset of the Full analysis set (FAS) population which included all randomized patients who took at least one dose of blinded post randomization study drug, had a measurement for analysis available in at least one treatment period and met lung function eligibility criteria specifically at the randomization visit.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "L (Liter)", "timeFrame": "Baseline and 2 Weeks", "groups": [{"id": "OG000", "title": "Montelukast + Mometasone", "description": "Inhaled montelukast 1mg (milligram) and open label mometasone 220 mcg (micrograms) once daily."}, {"id": "OG001", "title": "Placebo + Mometasone", "description": "Inhaled placebo for montelukast and open label mometasone 220 mcg once daily."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "99"}, {"groupId": "OG001", "value": "99"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.27", "lowerLimit": "0.19", "upperLimit": "0.35"}, {"groupId": "OG001", "value": "0.19", "lowerLimit": "0.12", "upperLimit": "0.26"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY", "pValue": "0.002", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Model with fixed effects for treatment, time (weeks 1 and 2), treatment-by-time interaction, period and baseline covariate.", "paramType": "Difference in Least-Squares Means", "paramValue": "0.08", "ciPctValue": "95", "ciLowerLimit": "0.03", "ciUpperLimit": "0.13", "estimateComment": "Least-Squares Means for average change from baseline are derived using appropriate contrast from mixed model with fixed effects for treatment, time (weeks 1 and 2), treatment-by-time interaction, period and baseline covariate."}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "eventGroups": [{"id": "EG000", "title": "Montelukast + Mometasone", "description": "Inhaled montelukast 1 mg (milligram) and open label mometasone 220 mcg (micrograms) once daily.", "seriousNumAffected": 1, "seriousNumAtRisk": 130, "otherNumAffected": 24, "otherNumAtRisk": 130}, {"id": "EG001", "title": "Placebo + Mometasone", "description": "Inhaled placebo for montelukast and open label mometasone 220 mcg once daily.", "seriousNumAffected": 1, "seriousNumAtRisk": 129, "otherNumAffected": 24, "otherNumAtRisk": 129}], "seriousEvents": [{"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 129}]}, {"term": "Acute respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 129}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 129}]}], "otherEvents": [{"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 129}]}, {"term": "Aphthous stomatitis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 129}]}, {"term": "Melaena", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 129}]}, {"term": "Stomach discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 129}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 129}]}, {"term": "Irritability", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 129}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 129}]}, {"term": "Acarodermatitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 129}]}, {"term": "Gastroenteritis viral", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 129}]}, {"term": "Herpes simplex", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 129}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 129}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 129}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 129}]}, {"term": "Pulpitis dental", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 129}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 129}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 129}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 129}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 129}]}, {"term": "Viral pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 129}]}, {"term": "Viral rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 129}]}, {"term": "Contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 129}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 129}]}, {"term": "Blood cholesterol increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 129}]}, {"term": "Eosinophil count increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 129}]}, {"term": "White blood cells urine positive", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 129}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 129}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 129}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 129}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 129}]}, {"term": "Allergic pharyngitis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 129}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 129}]}, {"term": "Asthmatic crisis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 129}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 129}]}, {"term": "Rhinorrhoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 129}]}, {"term": "Dermatitis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 129}]}, {"term": "Dermatitis atopic", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 129}]}, {"term": "Pityriasis rosea", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 130}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 129}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Canada", "Colombia", "Israel", "Mexico", "Peru", "United Kingdom", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068656", "term": "Mometasone Furoate"}, {"id": "C000093875", "term": "Montelukast"}], "ancestors": [{"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000020024", "term": "Leukotriene Antagonists"}, {"id": "D000006727", "term": "Hormone Antagonists"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000065694", "term": "Cytochrome P-450 CYP1A2 Inducers"}, {"id": "D000065693", "term": "Cytochrome P-450 Enzyme Inducers"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}], "browseLeaves": [{"id": "M290", "name": "Mometasone Furoate", "asFound": "At 3", "relevance": "HIGH"}, {"id": "M274108", "name": "Montelukast", "asFound": "Means", "relevance": "HIGH"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M21876", "name": "Leukotriene Antagonists", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}]}}, "hasResults": true}